The hypersensitivity reaction (HSR) associated with the antiretroviral abacavir does not usually have serious outcomes unless recognised late or following re-challenge. Pharmacogenetic testing of HLA B*5701 (B*5701) for HSR risk is being used increasingly in clinical practice backed by strong evidence among Caucasians and Hispanics1. In the Western Australian landmark studies, updated to improve diagnostic accuracy, positive and negative predictive values (PPV and NPV) of B*5701 for HSR were 78.9% and 99.4%1 respectively. When B*5701 screening was introduced into this cohort2, and in Brighton UK3, no HSR were observed in 148 and 185 B*5701 negative patients respectively treated with abacavir.
- Black African
- HLA B*5701